Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia Van Dam Sequist, Belinda A. Waltman, Dora C. Dias-Santagata et al. · Science Translational Medicine · 2011
Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate mechanisms of acquired drug resistance, we performed systematic genetic and histological analyses of tumor biopsies from 37 patients with drug-resistant non-small cell lung cancers (NSCLCs) carrying EGFR mutations. All drug-resistant tumors retained their original activating EGFR mutations, and some acquired known mechanisms of resistance including the EGFR T790M mutation or MET gene amplification. Some resistant cancers showed unexpected genetic changes including EGFR amplification and mutations in the PIK3CA gene, whereas others underwent a pronounced epithelial-to-mesenchymal transition. Surprisingly, five resistant tumors (14%) transformed from NSCLC into small cell lung cancer (SCLC) and were sensitive to standard SCLC treatments. In three patients, serial biopsies revealed that genetic mechanisms of resistance were lost in the absence of the continued selective pressure of EGFR inhibitor treatment, and such cancers were sensitive to a second round of treatment with EGFR inhibitors. Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease.
Cited by 3,494 works. doi:10.1126/scitranslmed.3002003
Authors
- Lecia Van Dam Sequist
- Belinda A. Waltman
- Dora C. Dias-Santagata
- Subba Rao Digumarthy
- Alexa B. Turke
- Panos M. Fidias
- Kristin E. Bergethon
- Alice Tsang Shaw
- Scott N. Gettinger
- Arjola K. Cosper
- Sara Akhavanfard
- Rebecca Suk Heist
- Jennifer S. Temel
- James G. Christensen
- John C. Wain
- Thomas James Lynch
- Kathy Vernovsky
- Eugene Jerome Mark
- Michael D. Lanuti
- Anthony John Iafrate
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial